Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.20 1 Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points) 2 Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY28 3 Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth 3,4 Raising long-term target for Other... Read More